Hepatic bromobenzene epoxidation and binding: prevention by ascorbyl palmitate

V. G. Zannoni, E. K. Marker, Serrine Lau

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism indicated no significant difference in the formation of products o-bromophenol and p-bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate were very effective in protecting against macromolecular adduct formation at a concentration of 1 mM - in fact, at least a twofold increase in protection compared to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene over 90% at a concentration of 2.5 mM.

Original languageEnglish (US)
Pages (from-to)193-204
Number of pages12
JournalDrug-Nutrient Interactions
Volume1
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Protective Agents
Liver
Mixed Function Oxygenases
Cytochrome P-450 Enzyme System
Glutathione
Cysteine
Necrosis
bromobenzene
6-O-palmitoylascorbic acid
Proteins
bromobenzene 3,4-oxide
4-bromophenol
2-bromophenol
bromobenzene 2,3-oxide
Metabolic Activation

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Hepatic bromobenzene epoxidation and binding : prevention by ascorbyl palmitate. / Zannoni, V. G.; Marker, E. K.; Lau, Serrine.

In: Drug-Nutrient Interactions, Vol. 1, No. 3, 1982, p. 193-204.

Research output: Contribution to journalArticle

@article{7e783660f3aa43fe9818fe33fd73a986,
title = "Hepatic bromobenzene epoxidation and binding: prevention by ascorbyl palmitate",
abstract = "Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism indicated no significant difference in the formation of products o-bromophenol and p-bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate were very effective in protecting against macromolecular adduct formation at a concentration of 1 mM - in fact, at least a twofold increase in protection compared to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene over 90{\%} at a concentration of 2.5 mM.",
author = "Zannoni, {V. G.} and Marker, {E. K.} and Serrine Lau",
year = "1982",
language = "English (US)",
volume = "1",
pages = "193--204",
journal = "Drug-Nutrient Interactions",
issn = "0272-3530",
number = "3",

}

TY - JOUR

T1 - Hepatic bromobenzene epoxidation and binding

T2 - prevention by ascorbyl palmitate

AU - Zannoni, V. G.

AU - Marker, E. K.

AU - Lau, Serrine

PY - 1982

Y1 - 1982

N2 - Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism indicated no significant difference in the formation of products o-bromophenol and p-bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate were very effective in protecting against macromolecular adduct formation at a concentration of 1 mM - in fact, at least a twofold increase in protection compared to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene over 90% at a concentration of 2.5 mM.

AB - Bromobenzene undergoes metabolic activation via 2,3- and 3,4-epoxidation catalyzed by the hepatic cytochrome P-450 mixed-function oxidase system. Its reactive metabolites, especially bromobenzene 3,4-oxide, presumably lead to severe centrolobular necrosis. A study of relative rate of binding of 14C-bromobenzene metabolites to hepatic microsomal protein indicated a significant difference in the rate of binding of the bromobenzene 3,4-oxide compared to its positional isomer, bromobenzene 2,3-oxide. However, the rate of bromobenzene metabolism indicated no significant difference in the formation of products o-bromophenol and p-bromophenol. A search for protective agents revealed that 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate were very effective in protecting against macromolecular adduct formation at a concentration of 1 mM - in fact, at least a twofold increase in protection compared to the known protective agents such as glutathione or cysteine. Furthermore, 6,7-dimethyl-5,6,7,8-tetrahydropterine and ascorbyl palmitate inhibited the metabolism of bromobenzene over 90% at a concentration of 2.5 mM.

UR - http://www.scopus.com/inward/record.url?scp=0020376629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020376629&partnerID=8YFLogxK

M3 - Article

C2 - 6926828

AN - SCOPUS:0020376629

VL - 1

SP - 193

EP - 204

JO - Drug-Nutrient Interactions

JF - Drug-Nutrient Interactions

SN - 0272-3530

IS - 3

ER -